PCA
TNYA icon

Pallas Capital Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Pallas Capital Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,832
Closed -$16.4K – 952
2025
Q2 		$16.4K Sell
26,832
-168
-0.6% -$86 ﹤0.01% 849
2025
Q1 		$15.4K Buy
+27,000
New +$26.6K ﹤0.01% 754

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Pallas Capital Advisors's TNYA Position: Q3 2025 in Review

Pallas Capital Advisors sold out of Tenaya Therapeutics (TNYA) in Q3 2025, closing a stake of 26,832 shares — an estimated $16.4K sold.

Pallas Capital Advisors first reported a position in TNYA in Q1 2025 and held it in 2 quarters. The position peaked at $16.4K in Q2 2025. 91 funds tracked by Wall St. Rank hold TNYA as of Q3 2025.

  • Pallas Capital Advisors reported no remaining Tenaya Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Pallas Capital Advisors sold 26,832 Tenaya Therapeutics shares in Q3 2025, an estimated $16.4K.
  • Pallas Capital Advisors first reported a position in Tenaya Therapeutics in Q1 2025 and held it in 2 quarters.
  • Pallas Capital Advisors's Tenaya Therapeutics position peaked at $16.4K in Q2 2025.
  • 91 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2025.

Based on Pallas Capital Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.